Yash B Joshi1, Michael L Thomas1, David L Braff1, Michael F Green1, Ruben C Gur1, Raquel E Gur1, Keith H Nuechterlein1, William S Stone1, Tiffany A Greenwood1, Laura C Lazzeroni1, Laura R MacDonald1, Juan L Molina1, John A Nungaray1, Allen D Radant1, Jeremy M Silverman1, Joyce Sprock1, Catherine A Sugar1, Debby W Tsuang1, Ming T Tsuang1, Bruce I Turetsky1, Neal R Swerdlow1, Gregory A Light1. 1. Desert Pacific Mental Illness Research, Education, and Clinical Center, VA San Diego Healthcare System, San Diego (Joshi, Braff, MacDonald, Molina, Light, Sprock); Department of Psychiatry, University of California, San Diego, La Jolla (Joshi, Braff, Swerdlow, Greenwood, MacDonald, Molina, Nungaray, Sprock, M.T. Tsuang, Light); Department of Psychology, Colorado State University, Fort Collins (Thomas); Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles (Green, Nuechterlein, Sugar); Desert Pacific Mental Illness Research, Education, and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles (Green); Department of Psychiatry, University of Pennsylvania, Philadelphia (R.C. Gur, R.E. Gur, Turetsky); Department of Psychiatry, Harvard Medical School, and Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston (Stone); Department of Psychiatry and Behavioral Sciences and Department of Biomedical Data Science, Stanford University, Stanford, Calif. (Lazzeroni); Sierra Pacific Mental Illness Research, Education, and Clinical Center, VA Health Care System, Palo Alto, Calif. (Lazzeroni); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Radant, D.W. Tsuang); Northwest Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle (Radant, D.W. Tsuang); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Silverman); Research and Development, James J. Peters VA Medical Center, New York (Silverman); Department of Biostatistics, UCLA School of Public Health, Los Angeles (Sugar).
Abstract
OBJECTIVE: Many psychotropic medications used to treat schizophrenia have significant anticholinergic properties, which are linked to cognitive impairment and dementia risk in healthy subjects. Clarifying the impact of cognitive impairment attributable to anticholinergic medication burden may help optimize cognitive outcomes in schizophrenia. The aim of this study was to comprehensively characterize how this burden affects functioning across multiple cognitive domains in schizophrenia outpatients. METHODS: Cross-sectional data were analyzed using inferential statistics and exploratory structural equation modeling to determine the relationship between anticholinergic medication burden and cognition. Patients with a diagnosis of schizophrenia or schizoaffective disorder (N=1,120) were recruited from the community at five U.S. universities as part of the Consortium on the Genetics of Schizophrenia-2. For each participant, prescribed medications were rated and summed according to a modified Anticholinergic Cognitive Burden (ACB) scale. Cognitive functioning was assessed by performance on domains of the Penn Computerized Neurocognitive Battery (PCNB). RESULTS: ACB score was significantly associated with cognitive performance, with higher ACB groups scoring worse than lower ACB groups on all domains tested on the PCNB. Similar effects were seen on other cognitive tests. Effects remained significant after controlling for demographic characteristics and potential proxies of illness severity, including clinical symptoms and chlorpromazine-equivalent antipsychotic dosage. CONCLUSIONS: Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains. Anticholinergic medication burden from all medication classes-including psychotropics used in usual care-should be considered in treatment decisions and accounted for in studies of cognitive functioning in schizophrenia.
OBJECTIVE: Many psychotropic medications used to treat schizophrenia have significant anticholinergic properties, which are linked to cognitive impairment and dementia risk in healthy subjects. Clarifying the impact of cognitive impairment attributable to anticholinergic medication burden may help optimize cognitive outcomes in schizophrenia. The aim of this study was to comprehensively characterize how this burden affects functioning across multiple cognitive domains in schizophrenia outpatients. METHODS: Cross-sectional data were analyzed using inferential statistics and exploratory structural equation modeling to determine the relationship between anticholinergic medication burden and cognition. Patients with a diagnosis of schizophrenia or schizoaffective disorder (N=1,120) were recruited from the community at five U.S. universities as part of the Consortium on the Genetics of Schizophrenia-2. For each participant, prescribed medications were rated and summed according to a modified Anticholinergic Cognitive Burden (ACB) scale. Cognitive functioning was assessed by performance on domains of the Penn Computerized Neurocognitive Battery (PCNB). RESULTS: ACB score was significantly associated with cognitive performance, with higher ACB groups scoring worse than lower ACB groups on all domains tested on the PCNB. Similar effects were seen on other cognitive tests. Effects remained significant after controlling for demographic characteristics and potential proxies of illness severity, including clinical symptoms and chlorpromazine-equivalent antipsychotic dosage. CONCLUSIONS: Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains. Anticholinergic medication burden from all medication classes-including psychotropics used in usual care-should be considered in treatment decisions and accounted for in studies of cognitive functioning in schizophrenia.
Entities:
Keywords:
Anticholinergics; Cognition/Learning/Memory; Psychopharmacology; Schizophrenia Spectrum and Other Psychotic Disorders
Authors: Rodolfo Solís-Vivanco; Felipe Rangel-Hassey; Pablo León-Ortiz; Alejandra Mondragón-Maya; Francisco Reyes-Madrigal; Camilo de la Fuente-Sandoval Journal: JAMA Psychiatry Date: 2020-05-01 Impact factor: 21.596
Authors: Bjørn Rishovd Rund; Helene Eidsmo Barder; Julie Evensen; Ulrik Haahr; Wenche ten Velden Hegelstad; Inge Joa; Jan Olav Johannessen; Johannes Langeveld; Tor Ketil Larsen; Ingrid Melle; Stein Opjordsmoen; Jan Ivar Røssberg; Erik Simonsen; Kjetil Sundet; Per Vaglum; Thomas McGlashan; Svein Friis Journal: Schizophr Bull Date: 2015-06-21 Impact factor: 9.306
Authors: Michael L Thomas; Michael F Green; Gerhard Hellemann; Catherine A Sugar; Melissa Tarasenko; Monica E Calkins; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Allen D Radant; Larry J Seidman; Alexandra L Shiluk; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff; Gregory A Light Journal: JAMA Psychiatry Date: 2017-01-01 Impact factor: 21.596
Authors: Neal R Swerdlow; Savita G Bhakta; Jo Talledo; Lindsay Benster; Juliana Kotz; Sophia Vinogradov; Juan L Molina; Gregory A Light Journal: Psychol Med Date: 2021-04-14 Impact factor: 10.592
Authors: Philip D Harvey; Marta Bosia; Roberto Cavallaro; Oliver D Howes; René S Kahn; Stefan Leucht; Daniel R Müller; Rafael Penadés; Antonio Vita Journal: Schizophr Res Cogn Date: 2022-03-22
Authors: Sofia Eickhoff; Leon Franzen; Alexandra Korda; Helena Rogg; Valerie-Noelle Trulley; Stefan Borgwardt; Mihai Avram Journal: Front Psychiatry Date: 2022-07-06 Impact factor: 5.435
Authors: Maija Lindgren; Sebastian Therman; Anna Avellan; Tiina From; Jarmo Hietala; Minna Holm; Tuula Ilonen; Tuula Kieseppä; Heikki Laurikainen; Raimo K R Salokangas; Jaana Suvisaari Journal: Schizophrenia (Heidelb) Date: 2022-08-04
Authors: Min Tae M Park; Peter Jeon; Leon French; Kara Dempster; M Mallar Chakravarty; Michael MacKinley; Julie Richard; Ali R Khan; Jean Théberge; Lena Palaniyappan Journal: Transl Psychiatry Date: 2022-09-01 Impact factor: 7.989
Authors: Giulia M Giordano; Francesco Brando; Pasquale Pezzella; Maria De Angelis; Armida Mucci; Silvana Galderisi Journal: Front Psychiatry Date: 2022-08-30 Impact factor: 5.435